Endocannabinoids and Cancer. [revisión]
Por: Sánchez, Cristina [Instituto de Investigación imas12]
.
Colaborador(es): Instituto de Investigación imas12.
Tipo de material: 
ArtículoEditor: Handbook of experimental pharmacology, 2015Descripción: 231:449-72.Recursos en línea: Solicitar documento Resumen: A large body of evidence shows that cannabinoids, in addition to their well-known palliative effects on some cancer-associated symptoms, can reduce tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and cell proliferation in different types of tumours in laboratory animals. By contrast, little is known about the biological role of the endocannabinoid system in cancer physio-pathology, and several studies suggest that it may be over-activated in cancer. In this review, we discuss our current understanding of cannabinoids as antitumour agents, focusing on recent advances in the molecular mechanisms of action, including resistance mechanisms and opportunities for combination therapy approaches.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Revisión
|
PC16966 (Navegar estantería) | Disponible |
Formato Vancouver:
Velasco G, Sánchez C, Guzmán M. Endocannabinoids and Cancer. Handb Exp Pharmacol. 2015;231:449-72.
PMID: 26408171
Contiene 94 referencias
A large body of evidence shows that cannabinoids, in addition to their well-known palliative effects on some cancer-associated symptoms, can reduce tumour growth in animal models of cancer. They do so by modulating key cell signalling pathways involved in the control of cancer cell proliferation and survival. In addition, cannabinoids inhibit angiogenesis and cell proliferation in different types of tumours in laboratory animals. By contrast, little is known about the biological role of the endocannabinoid system in cancer physio-pathology, and several studies suggest that it may be over-activated in cancer. In this review, we discuss our current understanding of cannabinoids as antitumour agents, focusing on recent advances in the molecular mechanisms of action, including resistance mechanisms and opportunities for combination therapy approaches.
No hay comentarios para este ejemplar.